Innate Pharma マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Jonathan Dickinson

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	6yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Jonathan Dickinson (56 yo)

no data

在職期間

Mr. Jonathan E. Dickinson served as Executive Vice President and General Manager of Europe at Incyte Corp. since June 2019 until October 2024. He served as General Manager of Europe/International and Senio...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yannis Morel	Executive VP	9.5yrs	€599.92k	0.24% € 312.7k
Jonathan Dickinson	Chairman of the Executive Board & CEO	no data	データなし	データなし
François Romagné	Founder	no data	データなし	データなし
Eric Vivier	Founder	6.8yrs	データなし	0.26% € 338.5k
Marc Bonneville	Founder	no data	データなし	データなし
Jean Fournié	Founder	no data	データなし	データなし
Alessandro Moretta	Founder	no data	データなし	データなし
Frederic Lombard	Senior VP & CFO	3.6yrs	データなし	0.014% € 18.3k
Sonia Quaratino	Executive VP	less than a year	データなし	データなし
Arvind Sood	Executive VP	less than a year	データなし	データなし
Henry Wheeler	Vice President of Investor Relations & Communication	1.8yrs	データなし	0.0039% € 5.1k
Odile Belzunce	Vice President of Compliance & Operations	5.8yrs	データなし	0.077% € 100.2k

2.7yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: IDDの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Mario Sznol	Strategic Advisory Board Member	6yrs	データなし	データなし
Olivier Martinez	Member of Supervisory Board	no data	データなし	データなし
Diane Mathis	Strategic Advisory Board	less than a year	データなし	データなし
Gilles Brisson	Independent Member of Supervisory Board	17.4yrs	€29.00k	0.090% € 117.6k
Sally Bennett	Independent Supervisory Board Member	2.5yrs	€45.00k	0.0031% € 4.0k
Jean-Yves Blay	Independent Member of Supervisory Board	6.9yrs	€29.00k	0.000060% € 78.2
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	15.4yrs	€42.00k	0.031% € 40.4k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	4.5yrs	€60.00k	0.0012% € 1.6k
Miriam Merad	Chairman of Strategic Advisory Board	6yrs	データなし	データなし
Veronique Chabernaud	Independent Member of Supervisory Board	9.6yrs	€48.00k	0.00082% € 1.1k
Katy Rezvani	Strategic Advisory Board	less than a year	データなし	データなし
Aurelien Marabelle	Strategic Advisory Board Member	6yrs	データなし	データなし

6.0yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: IDDの取締役会は経験豊富であると考えられます ( 6年の平均在任期間)。

Innate Pharma マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Innate Pharma SA Announces Board Changes

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Recent updates

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

First half 2024 earnings released: €0.31 loss per share (vs €0.021 profit in 1H 2023)

New minor risk - Profitability

New minor risk - Share price stability

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

New minor risk - Profitability

No longer forecast to breakeven

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Forecast to breakeven in 2026

Full year 2023 earnings released: €0.094 loss per share (vs €0.73 loss in FY 2022)

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

New minor risk - Share price stability

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022)

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

No longer forecast to breakeven

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

First half 2022 earnings released: EPS: €0.08 (vs €0.30 loss in 1H 2021)

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

First half 2021 earnings released: €0.30 loss per share (vs €0.13 loss in 1H 2020)

Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

Innate Pharma S.A. Announces New Lacutamab Data from Tellomak Trial in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma

Member of Supervisory Board Marcus Schindler has left the company

Full year 2020 earnings released

Full year 2020 earnings released

Innate Pharma S.A. Advances Lacutamab Clinical Development Program

Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

Rosen Law Firm Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action

Innate Pharma S.A., Annual General Meeting, May 28, 2021

Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

New 90-day low: €3.01

New 90-day low - €3.59

First half earnings released

New 90-day low - €5.11

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24